Adding Farxiga (dapagliflozin) to standard care significantly reduced the risk of death or worsening heart failure in older ...

With close collaboration between sponsors, CROs, and regulators, this emerging technology has the potential to greatly ...

Results from a subgroup of the ICONIC-LEAD study show 75% of adolescents with plaque psoriasis achieved completely clear skin ...

In the Phase III EXPECTS trial, patients experiencing mostly mild posterior circulation ischemic stroke who were ineligible ...

The clinical trial failure dilemma. What constitutes clinical trial failure is a matter of perspective. For sponsors, the ...

In this video interview, Derek Ansel, vice president, therapeutic strategy lead, rare disease, Worldwide Clinical Trials, discusses the most prominent challenges he is seeing in the space right now ...

Examining the implications of the recent US executive orders concerning diversity, equity, and inclusion pursuits—and the key ...

Tolebrutinib, a brain-penetrant BTK inhibitor, may fill a significant unmet need by delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis.

The future of clinical trial design involves incorporating the patient experience into strategic asset planning.

In this video interview, Thierry Escudier, portfolio lead, Pistoia Alliance, highlights the need for maintaining data privacy ...

As oncology research centers scale eSource adoption, the field is shifting toward a fully digital, clinical trial ecosystem.

In this video interview, Thierry Escudier, portfolio lead, Pistoia Alliance, highlights where regulatory agencies currently ...